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Abstract
Next generation sequencing (NGS) is routinely used in clinical genetic testing.
Quality management of NGS testing is essential to ensure performance is
consistently and rigorously evaluated.
Three primary metrics are used in NGS quality evaluation: depth of coverage,
base quality and mapping quality. To provide consistency and transparency in
the utilisation of these metrics we present the Quality Sequencing Minimum
(QSM).
The QSM defines the minimum quality requirement a laboratory has selected
for depth of coverage (C), base quality (B) and mapping quality (M) and can be
applied per base, exon, gene or other genomic region, as appropriate. The
QSM format is CX_BY(P )_MZ(P ). X is the parameter threshold for C, Y the
parameter threshold for B, P  the percentage of reads that must reach Y, Z the
parameter threshold for M, P  the percentage of reads that must reach Z. The
data underlying the QSM is in the BAM file, so a QSM can be easily and
automatically calculated in any NGS pipeline.
We used the QSM to optimise cancer predisposition gene testing using the
TruSight Cancer Panel (TSCP). We set the QSM as C50_B10(85)_M20(95).
Test regions falling below the QSM were automatically flagged for review, with
100/1471 test regions QSM-flagged in multiple individuals. Supplementing
these regions with 132 additional probes improved performance in 85/100. We
also used the QSM to optimise testing of genes with pseudogenes such as 
 and  . In TSCP data from 960 individuals the median number ofPTEN PMS2
regions that passed QSM per sample was 1429 (97%).  Importantly, the QSM
can be used at an individual report level to provide succinct, comprehensive
quality assurance information about individual test performance.
We believe many laboratories would find the QSM useful. Furthermore,
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 We believe many laboratories would find the QSM useful. Furthermore,
widespread adoption of the QSM would facilitate consistent, transparent
reporting of genetic test performance by different laboratories.
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Introduction
Next generation sequencing (NGS) is now routinely used to 
investigate if genomic variation has caused, or has the potential 
to cause human disease in clinical and research settings1. Such 
genetic tests must robustly be able to detect pathogenic variants 
(positive tests) and to exclude the presence of pathogenic variants 
(negative tests). The accuracy of NGS in this regard is depend-
ent on the performance of the assay generating the sequence 
data and the software tools that analyse the data. Suboptimal 
technical and/or analytical performance can lead to false posi-
tive or false negative results. Comprehensive quality manage-
ment of NGS pipelines is thus essential and must encompass 
both quality assurance and quality control2. Guidelines for 
quality management of the technical and analytical aspects of 
clinical NGS pipelines have been published2–6. One of the 
recommendations is for clear information about test performance 
and limitations to be provided on the test report, as healthcare 
professionals need this for clinical decision making3–5. Although 
this is well accepted to be best practice there are no specific 
guidelines for how it can be achieved, and most test reports 
provide limited or no information.
Three primary metrics are used to evaluate sequence quality in 
NGS data: depth of coverage (how many sequence reads are 
present at a given position), base quality (have the correct bases 
been called in sequence reads) and mapping quality (have the reads 
been mapped to the correct position in the genome)7.
Insufficient depth of coverage is a common cause of false nega-
tive errors8. A summary statement of coverage, such as the 
minimum depth or average depth of coverage achieved is 
often provided as a proxy for overall performance. However, 
using only the number of reads is not a sufficient measure of 
performance. False negative errors can still occur even with 
good depth of coverage, for example if the reads have been 
aligned incorrectly to the genome. Moreover, depth of coverage 
has limited utility in reducing false positive errors. Base quality 
and mapping quality are useful for this and most NGS base call-
ers and read mappers provide Phred-scaled quality scores that 
quantify the probability that a particular base has been identified 
incorrectly (base quality score, BQ)9, or a read has aligned 
to the wrong genomic position (mapping quality score, MQ)10.
Quality assurance of an NGS test therefore requires attention 
to the quality control of depth of coverage, base quality and 
mapping quality during the design, optimisation and utilisa-
tion of the test. To bring consistency and transparency to these 
processes we have developed and implemented the Quality 
Sequencing Minimum (QSM). The QSM defines the minimum 
quality requirement that a laboratory has selected for depth of 
coverage (C), base quality (B) and mapping quality (M) and 
can be applied per base, exon, gene, or other genomic region, 
as appropriate. The QSM allows consistent, automated flag-
ging of test regions that fall below minimum quality require-
ments and thus need additional scrutiny. In addition to its use in 
optimisation and quality control of NGS pipelines, the QSM can 
be used at an individual report level to provide succinct, 
comprehensive quality assurance information about individual test 
performance.
A standard BAM file contains the data required for the QSM 
and a QSM can be easily and automatically applied in any 
NGS pipeline. We have developed a freely available tool called 
CoverView to do this11. Alternatively, custom scripting within any 
NGS analytical pipeline should readily allow application of a 
QSM. 
We have found use of a QSM a highly effective and efficient 
way to meet the quality management recommendations for NGS 
testing, and we believe others may also find it useful. Further-
more, general adoption of the QSM would help to standardise 
the communication of NGS quality information by the thousands 
of laboratories now undertaking NGS tests.
Methods
A QSM includes three sequence quality metrics: depth of cover-
age (C), base quality (B), and mapping quality (M). The values 
for these metrics are dependent on the tools used to generate them. 
The standardised format for a fully comprehensive QSM is:
CX_BY(PY)_MZ(PZ) using 1v1_2v2_..._nvn
Where X is the parameter threshold for C, Y is the parameter 
threshold for B, PY is the percentage of reads that must reach 
Y, Z is the parameter threshold for M, PZ is the percentage 
of reads that must reach Z, and 1v1 through nvn are the tool 
name(s) and version(s) for read, base and mapping quality score 
generation, and variant calling.
Metric C uses the number of sequencing reads (depth of 
coverage) that have mapped to the reference genome for a given 
base position. Metric B uses the BQ of a base call that quan-
tifies the probability that the base calling is incorrect. Metric 
M uses the MQ that quantifies the probability that a read is 
mapped to the wrong position during alignment.
The test region for which a QSM is generated is supplied in a 
BED file and the C, B, M values are in the sample’s BAM file 
and corresponding .BAI file. These are all routinely outputted 
by NGS analysis pipelines and used by the variant caller 
to detect and assign confidence to variant calls.
Variant callers apply data filtering at both the read-level and 
the base-level. Use of a preset parameter to exclude data is 
called ‘hard filtering’. If the variant caller performs hard filter-
ing, these parameters should be used to define the minimum 
quality requirements for C, B and M. If the caller performs hard 
filtering at a read-level, but not at a base-level, the minimum 
quality requirement can be defined in a more flexible fashion.
The actual quality of NGS data generated may be well above 
a QSM, but any data of lower quality for any of the three 
metrics is automatically flagged for additional scrutiny. 
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Results
Setting a QSM
TGLclinical is an ISO 15189 accredited clinical testing labo-
ratory providing cancer predisposition gene testing using the 
TruSight Cancer Panel (TSCP)12. TSCP uses Nextera® library 
preparation technology (Illumina, San Diego, CA, USA) and 
in-solution hybrid-selection chemistry for targeted enrichment. 
The TGLclinical analytical pipeline includes CASAVA v.1.8.2 
to demultiplex and create FASTQs per sample from the raw 
base call (BCL) files and Stampy v.1.0.2013 with BWA v.0.7.5a 
pre-mapping14 to map sequence reads to the human refer-
ence genome (GRCh37). The pipeline uses Platypus v.0.2.415 
for variant calling of base substitutions and indels. 
The full QSM for TSCP testing in TGLclinical is:
C50_B10(85)_M20(95) using CASAVAv1.8.2_BWAv0.7.5a_
Stampyv1.0.20_Platypusv0.2.4
This means that 100% of the constituent bases of the test region 
must minimally have a depth of coverage of ≥50 reads with a 
BQ of ≥10 in at least 85% of reads, and MQ of ≥20 in at least 
95% of reads. The rationale for these choices is explained below.
For the QSM depth of coverage we selected C50, i.e. ≥50 reads 
per base. The average depth of coverage achieved for the TSCP 
pipeline in TGLclinical is >1000x. We consider a base position 
that fails to achieve 5% of the average depth of coverage 
(i.e. <50 reads) as suboptimal and requiring further evaluation. 
For many pipelines with much lower average depth of 
coverage, C50 would likely be too high, and would lead to an 
intolerably large number of additional evaluations.
For the QSM base quality minimum we selected B10(85), i.e. 
a BQ of ≥10 in at least 85% of reads. Platypus v.0.2.4, the vari-
ant caller used in TGLclinical, performs hard filtering at the 
read-level, discarding reads that have fewer than 20 bases with 
a quality score of BQ ≥20. Platypus uses retained reads to call 
variants, without hard filtering at the base-level, such that bases 
with BQ<20 in retained reads are used for calling variants. 
Bases of low quality tend to occur at the ends of reads16, but to 
mitigate the impact of this, the TSCP probes are densely spaced 
giving read overlap. This means that a base can have a proportion 
of low (BQ<20) quality bases yet still have sufficient high 
quality bases for variant calling. To accommodate this we set the 
BQ minimum as 10 in at least 85% of reads.
For the QSM mapping quality minimum we selected M20(95), 
i.e. a MQ of ≥20 in at least 95% of reads. Platypus uses a 
mapping quality threshold of MQ ≥20 to perform hard filtering 
at the read-level. MQ is only generated per read so this hard filter 
also applies at the base-level. MQ is a reflection of the sequence 
context of the region. In a region with unique sequence 
context (i.e. not of low complexity or high homology with 
another part of the genome), only a small proportion of reads 
would have a low MQ by chance. We thus set the MQ minimum 
as 20 in at least 95% of reads.
Using the QSM for optimisation and quality control of NGS 
pipelines
We have run TSCP in >20,000 samples and we have used the 
QSM in various ways to optimise TSCP testing as outlined 
below. Here we have specifically used TSCP data from 960 
samples tested through the TGLclinical pipeline. The samples had 
been tested for one of two reasons: 1) The samples had under-
gone clinical diagnostic testing, the consent for which includes 
consent for quality assurance, audit and research. 2) The samples 
had been tested through our research studies to discover and 
characterise cancer predisposition genes, with written informed 
consent obtained. The research studies have been approved 
by the London Multicentre Research Ethics Committee 
(MREC/01/2/18, 05/MRE02/17, MREC/01/2/044) and Royal 
Marsden Research Ethics Committee (CCR1922).
As part of our automated NGS analysis pipeline sample BAM 
files with their corresponding .BAI index files are inputted into 
CoverView11. We defined 1471 test regions in a BED file. Any 
test region falling below QSM C50_B10(85)_M20(95) for any 
of the three metrics was automatically flagged by CoverView 
in each sample (Dataset 1)17.
To optimise TSCP we viewed each QSM-flagged region in the 
CoverView GUI by plotting the per base values for each qual-
ity metric C, B and M. Using the genomic coordinates of the 
TSCP 80-mer probes as a reference, we strategically designed 
additional probes across the QSM-flagged regions. In total 
we supplemented 100 test regions with 132 additional probes. 
This improved quality with 85/100 boosted regions meeting 
QSM C50_B10(85)_M20(95)17. The booster probe set is now 
routinely analysed together with the original panel in all our 
tests. We call this the Optimised TSCP. 
Using the Optimised TSCP data for the 960 samples we output-
ted the number of samples in which the quality minimum for 
C, B, and/or M was not met, for each test region (Dataset 1)17. 
Regions in which >1% of samples (i.e. ten or more samples) 
had not passed the quality minimum were reviewed. Across the 
960 samples 1427/1471 (97%) test regions met C50, 1456/1471 
(99%) met B10(85) and 1411/1471 (96%) met M20(95). 
Overall 1366/1471 (93%) test regions met QSM C50_B10(85)_
M20(95). Per sample, the median number of regions that met 
QSM C50_B10(85)_M20(95) was 1429 (97%).
Detailed review of regions that were QSM-flagged in mul-
tiple individuals proved very useful for optimising TSCP 
performance. For example, some regions in genes with pseu-
dogenes, such as PTEN and PMS2, were frequently flagged 
as not meeting M20(95). We evaluated these regions to see 
if the data was usable for variant calling. PTEN is located on 
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chromosome 10q23 and has a pseudogene known as PTENP1 on 
chromosome 9p13. The coding sequences of PTEN and PTENP1 
are identical apart from 18 dispersed bases (comparing 
ENST00000371953.3 for PTEN with ENST00000447117.1 
for PTENP1), but the intronic sequences do not match. The 
high homology between PTEN and PTENP1 leads to low 
mapping quality scores and five PTEN regions were flagged 
for not meeting the minimum requirement of M20(95) in 
the QSM evaluation data (Dataset 1)17. To further evaluate 
PTEN testing performance with TSCP we reviewed data 
from 8133 samples. 47 different variants in 72 samples were 
detected, of which 18 were confirmed by Sanger sequencing 
and 29 were not confirmed17. We also generated TSCP data in 
an additional 14 samples in which PTEN variants, in exons 2, 
3, 5, 6, 7 and 9, had been identified by another method. All 14 
were detected by TSCP. These data show that mapping quality 
below M20(95) does not compromise the detection of PTEN 
true positives and has a very low false positive rate of 0.4% 
(33/8133). We therefore do not routinely repeat PTEN regions 
that do not meet M20(95).
Our review of the QSM-flagged regions in PMS2 led to a dif-
ferent conclusion. PMS2 is on 7p22 and has a nearby pseudog-
ene, called PMS2CL, that has high homology (>98%) for exons 
12-15. All 960 samples failed M20(95) for exons 12-15 and 
the median proportion of reads with low mapping quality was 
52–99% for these exons. To evaluate performance we used long-
range PCR to avoid the pseudogene sequence, and evaluated 63 
different variants detected amongst 4128 samples analysed by 
TSCP. 43/46 (93%) variants in exons 1-11 were confirmed. Only 
10/17 (59%) variants in exons 12-15 were confirmed (Dataset 1)17. 
We also reviewed the Sanger data for any additional vari-
ants that were not detected by TSCP and three variants, 
all in exon 14, were observed. Finally we generated TSCP 
data in five samples with PMS2 variants, in exons 3, 4, 10 and 
11, which had been detected by another method. All five were 
detected by the TSCP pipeline. Taken together these data show 
that TSCP performance for PMS2 exons 1-11 is excellent, and 
fulfils the QSM. However, TSCP data for PMS2 exons homolo-
gous to PMS2CL can lead to false negative and false positive 
results, and do not routinely fulfil the QSM. Therefore, if 
PMS2 gene testing is requested we first perform TSCP, and 
if negative we perform Sanger sequencing with long-range 
PCR primers that avoid PMS2CL.
Using a QSM on a gene test report
Detailed information about how the QSM was set and used to 
optimise testing would be provided in a laboratory’s full docu-
mentation and accreditation information. However, we believe 
the QSM also has potential utility at an individual report level. 
The QSM can succinctly provide consistent, transparent, com-
prehensive information about the performance of an individual 
test. This can be included on the individual test report and could 
be provided in different ways as shown in Table 1. Our personal 
preference is to include the short QSM statement ‘This test met 
QSM C50_B10(85)_M20(95)’. For tests in which some 
regions have not met QSM and were not repeated, for example 
because a pathogenic mutation was found in another gene, we 
would include a statement such as ‘This test met QSM 
C50_B10(85)_M20(95) {except PMS2 exons 12-15}’. This 
provides clarity about the genes that have been fully or subopti-
mally tested.
Table 1. Potential QSM statements for inclusion on genetic test report.
QSM statement 
type
QSM 
met
TGLclinical report QSM statement example
Short QSM Yes This test met QSM C50_B10(85)_M20(95) 
Short QSM No This test met QSM C50_B10(85)_M20(95) {except PMS2 exons 
12-15} 
Full QSM Yes This test met QSM C50_B10(85)_M20(95) using CASAVAv1.8.2_
BWAv0.7.5a_Stampyv1.0.20_Platypusv0.2.4 
Full QSM No This test met QSM C50_B10(85)_M20(95) using CASAVAv1.8.2_
BWAv0.7.5a_Stampyv1.0.20_Platypusv0.2.4 {except PMS2 exons 
12-15} 
Summary QSM Yes This test met QSM 
Summary QSM No This test met QSM {except PMS2 exons 12-15} 
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Conclusion
Quality assurance and quality control are essential require-
ments for genetic testing. It has proved challenging for 
laboratories to communicate how they are fulfilling these require-
ments for NGS tests. We have developed the Quality Sequencing 
Minimum (QSM), to achieve this. The QSM defines the mini-
mum quality requirement a laboratory has selected for depth of 
coverage, base quality and mapping quality. The QSM is easy to 
generate and can be flexibly applied per base, exon, gene, or 
other genomic region, as best suits the laboratory. The QSM 
is very useful in the optimisation and quality control of NGS 
pipelines, allowing consistent, automated flagging of test 
regions that fall below the designated minimum quality require-
ments. The QSM can also be used at an individual report level 
to provide succinct, comprehensive quality assurance information 
about individual test performance. Widespread adoption of 
the QSM would facilitate consistent, transparent reporting 
of genetic test performance by different laboratories.
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   Xiangtao Liu
 University of Iowa, Iowa City, IA, USA
 Tianjia Genomes LLC, Chaohu, Anhui, China
This paper presents a summary quality metric set QSM for NGS-based clinical assays, and its application
to real clinical sequencing data collected from the cancer predisposition gene testing TGLclinical.
While the three metrics contained in QSM are straightforward, the authors provided beneficial insights for
panel-based clinical assays using real data. The evaluation on regions of genes with pseudogenes is nice
work.
The authors may extend to some work about effects of tumor purity, in additional to consideration on
somatic mutations suggested by Erika.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Bioinformatics, statistical genetics
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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 I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 06 June 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.15568.r33208
 Ira M Lubin
Primary lead of the Next-Generation Sequencing Standards for Clinical Testing, Centers for Disease
Control and Prevention, Atlanta, GA, USA
Mahamdallie  describe a much needed metric useful to the reporting of next-generation sequencinget al 
results.  There are a few elements within the manuscript requiring further clarification that are needed to
support the validity of what is proposed.
1. Page 3.  The paragraph beginning with "Variant callers apply data filtering at both...." Additional
language will be useful in describing how this influences the QSM.  Variation in filtering can affect this
score suggesting that some provision may be needed in describing how filtering is applied.
2.  Page 3.  The paragraph beginning with "The actual quality of NGS data generated may be well
above......" Related to this is the paragraph that begins on Page 4 beginning with "Detailed review of
regions that were QSM-flagged........."  It is not clear when to know when to tag lower quality findings and
if such findings occur, are the authors alluding to the idea that the QSM score does not apply in these
cases.  Additional discussion regarding when the QSM is valid and not valid, what additional criteria
should be reported to support these findings, in a general sense, should be described.  If all lower scores
require further evaluation, this seems to defeat the intended simplicity of this measure.  In tagging low
quality reads, does this indicate, sometimes, that the parameters set were too high?
Page 4  Paragraph beginning with "For the QSM depth of coverage, we selected C50...."  Selection of
coverage at C50 seems to be somewhat arbitrary.  It would be helpful if additional evidence or published
studies can be cited.
Page 4. Paragraph beginning with "For the QSM base quality minimum we selected B10(85)." and "For
the QSM mapping quality minimum we selected M20(95)..."  The values chosen are rationalized in
considering the filtering and analysis that Platypus provides.  There should be discussion regarding how
this may vary using other methods.  This is somewhat addressed in Table 1 with the proposed format that
includes the software used.  Additional discussion with the text would be helpful.  In reporting, one may
also need to describe the application of QSM in conjunction with the types of variants targeted (e.g.,
SNPS, indels, repeats), each of which may have different requirements.  In addition allelic fraction may be
important for cancer and mosaic samples.  This should be recognized within the text as a potential
confounder.
Is the rationale for developing the new method (or application) clearly explained?
Partly
Is the description of the method technically sound?
Partly
Are sufficient details provided to allow replication of the method development and its use by
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 Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Partly
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Application of next-generation sequencing for clinical applications
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 16 April 2018Referee Report
https://doi.org/10.21956/wellcomeopenres.15568.r32746
 Erika Souche
Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium
This paper describes a summary quality metric, Quality Sequencing Minimum (QSM), for Next Generation
Sequencing based clinical assays. The proposed metric aims at assessing informative coverage in the
region of interest as it only takes into account depth of coverage, base quality and mapping quality. The
authors demonstrated the use of QSM during the development of a new assay where QSM allowed them
to spot difficult to amplify/sequence regions. While some regions could be recovered by designing
additional probes, some remained problematic. The authors thus checked whether their assay was able
to properly genotype known mutations in difficult regions and adapted their diagnostic routing according
to the results. Finally, the authors proposed to state QSM in the genetic test report.
QSM can be a good alternative to genotype quality when using variant callers that do not compute
genotype quality for reference calls. It would be interesting to compare genotype quality (from GATK for
example) to QSM to see whether the same regions are flagged.
While the QSM is generally well defined, it is difficult to understand why Py represents a proportion of
reads and not a proportion of bases with a base quality above Y. Is one read included in the proportion if
all its bases have a base quality above Y?
In the introduction, "The QSM defines the minimum quality requirement that a laboratory has selected for
depth of coverage (C), base quality (B) and mapping quality (M) and can be applied per base, exon,
gene, or other genomic region, as appropriate", it should be clear that the QSM should be defined at the
genetic test level, not at the laboratory level. For example the QSM will probably differ greatly
between tests designed for somatic and germline mutations.
Finally it would be nice to mention "informative coverage" and "region of interests (ROI)" as these are
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 Finally it would be nice to mention "informative coverage" and "region of interests (ROI)" as these are
established concepts in clinical genetic testing.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Bioinformatics, genetic testing
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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